Warning to GPs over rosiglitazone safety
NHS prescribing advisers have waded into the debate over the safety of rosiglitazone, warning the evidence suggested GPs should be ‘very cautious' over its use.
The National Prescribing Centre concluded in its latest MeReC Extra bulletin there was evidence that the drug might indeed raise the risk of myocardial infarction.
It was also associated with adverse effects on LDL cholesterol, weight and rates of congestive heart failure, the centre warned.
It pointed to a recent analysis in the New England Journal of Medicine linking use of the drug to increased rates of MI, and emphasised that these estimated dangers were applied to patients with a ‘low baseline risk' of MI – only 0.8% over two years.
The report concluded: ‘Many patients with diabetes will be at a higher cardio-Vascular risk than this. It raises important questions regarding the cardiovascular safety of rosiglitazone.'
It added that controlling the blood pressure of patients with type 2 diabetes was more effective than the control of blood glucose, and that metformin was the drug of first choice – especially with patients who were overweight.